Spero Therapeutics (STU:2HA) Cyclically Adjusted PS Ratio: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2HA Spero Therapeutics Inc STU:2HA
46 GF Score
Price €1.07
GF Value €0.69
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Spero Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Spero Therapeutics  (STU:2HA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Spero Therapeutics Cyclically Adjusted PS Ratio Related Terms


Spero Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Cyclically Adjusted PS Ratio Chart

Spero Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spero Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 3.43 0.00

STU:2HA vs ACRV, BSEM, RNTX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Spero Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Cyclically Adjusted PS Ratio falls into.


STU:2HA
46GF Score
Spero Therapeutics Inc STU:2HA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Spero Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Spero Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Spero Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.028 251.989 0.037
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.196 254.202 0.257
201906 0.108 256.143 0.141
201909 0.226 256.759 0.294
201912 -0.462 256.974 -0.600
202003 0.079 258.115 0.102
202006 0.074 257.797 0.096
202009 0.155 260.280 0.199
202012 -0.215 260.474 -0.276
202103 0.000 264.877 0.000
202106 0.059 271.696 0.073
202109 0.019 274.310 0.023
202112 0.007 278.802 0.008
202203 0.007 287.504 0.008
202206 0.026 296.311 0.029
202209 0.030 296.808 0.034
202212 0.896 296.797 1.008
202303 0.013 301.836 0.014
202306 0.014 305.109 0.015
202309 0.416 307.789 0.451
202312 1.216 306.746 1.324
202403 0.072 312.332 0.077
202406 0.104 314.175 0.111
202409 0.130 315.301 0.138
202412 0.164 315.605 0.174
202503 0.085 319.799 0.089
202506 0.183 322.561 0.189
202509 0.046 324.800 0.047
202512 0.494 324.054 0.509
202603 0.004 330.213 0.004
202606 0.000 333.952 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Spero Therapeutics (STU:2HA) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of €1.07 is trading 55.2% above its estimated GF Value™ of €0.69. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:2HA:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.69 vs. price of €1.07 (55.2% above fair value)
  • GF Score™: 46/100 with 2 warning signs

No single metric tells the full story. See the STU:2HA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spero Therapeutics Business Description

Other Exchanges SPRO:USA
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
46GF Score

Get the complete analysis for STU:2HA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.07
Price
€0.69
GF Value